{"id":"tetrandrine-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL176045","moleculeType":"Small molecule","molecularWeight":"622.76"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tetrandrine acts as a non-selective calcium channel antagonist, inhibiting both L-type and T-type calcium channels in various cell types. This mechanism reduces inflammatory mediator release from immune cells and suppresses T-cell proliferation, making it useful in treating autoimmune and inflammatory conditions. It also exhibits antifibrotic properties by inhibiting myofibroblast differentiation and collagen synthesis.","oneSentence":"Tetrandrine is a bisbenzylisoquinoline alkaloid that blocks calcium channels and modulates immune responses, primarily used as an anti-inflammatory and immunosuppressive agent.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:54.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Silicosis and pulmonary fibrosis"},{"name":"Autoimmune and inflammatory disorders"}]},"trialDetails":[{"nctId":"NCT07319598","phase":"PHASE4","title":"A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-11-02","conditions":"Interstitial Lung Disease (ILD), Connective Tissue Disease-associated Interstitial Lung Disease","enrollment":100},{"nctId":"NCT05697029","phase":"PHASE4","title":"Tetrandrine Tablets Used in Hospitalized Adults With COVID-19","status":"WITHDRAWN","sponsor":"Peking University Third Hospital","startDate":"2023-12-31","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04308317","phase":"PHASE4","title":"Tetrandrine Tablets Used in the Treatment of COVID-19","status":"UNKNOWN","sponsor":"Henan Provincial People's Hospital","startDate":"2020-03-05","conditions":"Corona Virus Disease 2019,COVID-19","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tetrandrine Tablets","genericName":"Tetrandrine Tablets","companyName":"Peking University Third Hospital","companyId":"peking-university-third-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tetrandrine is a bisbenzylisoquinoline alkaloid that blocks calcium channels and modulates immune responses, primarily used as an anti-inflammatory and immunosuppressive agent. Used for Rheumatoid arthritis, Silicosis and pulmonary fibrosis, Autoimmune and inflammatory disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}